🇺🇸 FDA
Patent

US 10420751

Methods of treating inflammatory bowel disease with AMD3100 and tacrolimus

granted A61KA61K31/00A61K31/365

Quick answer

US patent 10420751 (Methods of treating inflammatory bowel disease with AMD3100 and tacrolimus) held by MedRegen, LLC expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
MedRegen, LLC
Grant date
Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/00, A61K31/365, A61K31/395, A61K31/436